Hurdles Associated with the Translational Use of Genetically Modified Cells
- 47 Downloads
Purpose of Review
Recent advancements in the use of genetically modified hematopoietic stem cells (HSCs) and the emergent use of chimeric antigen receptor (CAR) T cell immunotherapy has highlighted issues associated with the use of genetically engineered cellular products. This review explores some of the challenges linked with translating the use of genetically modified cells.
The use of genetically modified HSCs for ADA-SCID now has European approval and the U.S. Food and Drug Administration recently approved the use of CAR T cells for relapsed/refractory B cell acute lymphoblastic leukemia. Current good manufacturing processes have now been developed for the collection, expansion, storage, modification, and administration of genetically modified cells.
Genetically engineered cells can be used for several therapeutic purposes. However, significant challenges remain in making these cellular therapeutics readily available. A better understanding of this technology along with improvements in the manufacturing process is allowing the translation process to become more standardized.
KeywordsLentiviral vector Transduction of hematopoietic stem cells Chimeric antigen receptor Genetic engineering
Compliance with Ethical Standards
Conflict of Interest
Sunil S. Raikar and H. Trent Spencer declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 3.Penati R, Fumagalli F, Calbi V, Bernardo ME, Aiuti A. Gene therapy for lysosomal storage disorders: recent advances for metachromatic leukodystrophy and mucopolysaccaridosis I. J Inherit Metab Dis. 2017;40(4):543–54. https://doi.org/10.1007/s10545-017-0052-4.CrossRefPubMedPubMedCentralGoogle Scholar
- 5.•• Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med. 2002;346(16):1185–93. Hematopoietic stem cells were among the first successful targets for gene addition, as described in this article. CrossRefPubMedGoogle Scholar
- 6.•• Ribeil JA, Hacein-Bey-Abina S, Payen E, Magnani A, Semeraro M, Magrin E, et al. Gene therapy in a patient with sickle cell disease. N Engl J Med. 2017;376(9):848–55. This is the first published case of a patient with sickle cell disease being successfully treated with genetically modified autologous hematopoetic stem cells. CrossRefPubMedGoogle Scholar
- 8.Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73. https://doi.org/10.1126/scitranslmed.3002842.CrossRefPubMedPubMedCentralGoogle Scholar
- 11.• Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517–28. This is one of the first clinical trials that used autologous T cells genetically modified to express CD19-directed chimeric antigen receptors to treat patients with relapsed/refractory B cell acute lymphoblastic leukemia. CrossRefPubMedGoogle Scholar
- 16.Mirzaei HR, Mirzaei H, Lee SY, Hadjati J, Till BG. Prospects for chimeric antigen receptor (CAR) gammadelta T cells: a potential game changer for adoptive T cell cancer immunotherapy. Cancer Lett. 2016;380(2):413–23. https://doi.org/10.1016/j.canlet.2016.07.001.CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Schwartz J, Winters JL, Padmanabhan A, Balogun RA, Delaney M, Linenberger ML, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher. 2013;28(3):145–284. https://doi.org/10.1002/jca.21276.CrossRefPubMedGoogle Scholar
- 27.Duong HK, Savani BN, Copelan E, Devine S, Costa LJ, Wingard JR, et al. Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2014;20(9):1262–73. https://doi.org/10.1016/j.bbmt.2014.05.003.CrossRefPubMedGoogle Scholar
- 31.Kondo M, Sakuta K, Noguchi A, Ariyoshi N, Sato K, Sato S, et al. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy. 2008;10(8):842–56. https://doi.org/10.1080/14653240802419328.CrossRefPubMedGoogle Scholar
- 33.• Karnieli O, Friedner OM, Allickson JG, Zhang N, Jung S, Fiorentini D, et al. A consensus introduction to serum replacements and serum-free media for cellular therapies. Cytotherapy. 2017;19(2):155–69. This review describes the state of the art usefulness of serum-free media. CrossRefPubMedGoogle Scholar
- 34.McGillicuddy N, Floris P, Albrecht S, Bones J. Examining the sources of variability in cell culture media used for biopharmaceutical production. Biotechnol Lett. 2017; https://doi.org/10.1007/s10529-017-2437-8.
- 38.Kotterman MA, Chalberg TW, Schaffer DV. Viral vectors for gene therapy: translational and clinical outlook. Annu Rev Biomed Eng. 2015;17(1):63–89. https://doi.org/10.1146/annurev-bioeng-071813-104938.CrossRefPubMedGoogle Scholar
- 50.Hollyman D, Stefanski J, Przybylowski M, Bartido S, Borquez-Ojeda O, Taylor C, et al. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother. 2009;32(2):169–80. https://doi.org/10.1097/CJI.0b013e318194a6e8.CrossRefPubMedPubMedCentralGoogle Scholar
- 61.Zonari E, Desantis G, Petrillo C, Boccalatte FE, Lidonnici MR, Kajaste-Rudnitski A, et al. Efficient ex vivo engineering and expansion of highly purified human hematopoietic stem and progenitor cell populations for gene therapy. Stem Cell Rep. 2017;8(4):977–90. https://doi.org/10.1016/j.stemcr.2017.02.010.CrossRefGoogle Scholar
- 62.Zhao Y, Stepto H, Schneider CK. Development of the first World Health Organization lentiviral vector standard: toward the production control and standardization of lentivirus-based gene therapy products. Hum Gene Ther Methods. 2017;28(4):205–14. https://doi.org/10.1089/hgtb.2017.078.CrossRefPubMedPubMedCentralGoogle Scholar
- 63.Stefan Radtke JA, Morgan Giese, Yan-Yi Chan, Zachary Norgaard, Mark Enstrom, Kevin Haworth, Lauren Schefter, Hans-Peter Kiem. A distinct hematopoietic stem cell population for rapid multilineage engraftment in nonhuman primates. Sci Transl Med. 2017;9(414).Google Scholar